SCHEMBL13609362

SCHEMBL13609362

C=C(C)[C@]1(C)CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 13/20 0.57
CNR1 P21554 10/20 0.57
OPRM1 P35372 6/20 0.57
TRPV1 Q8NER1 3/20 0.57
TRPM8 Q7Z2W7 3/20 0.57
GPR55 Q9Y2T6 3/20 0.57
NR1I2 O75469 2/20 0.57
LDHA P00338 2/20 0.57
CYP1A1 P04798 2/20 0.57
CYP2D6 P10635 2/20 0.57
CYP2B6 P20813 2/20 0.57
SLC6A2 P23975 2/20 0.57
CYP2C19 P33261 2/20 0.57
SLC6A3 Q01959 2/20 0.57
MLNR O43193 1/20 0.57
PDE9A O76083 1/20 0.57
ABCB11 O95342 1/20 0.57
CYP1A2 P05177 1/20 0.57
CHRM2 P08172 1/20 0.57
CYP3A4 P08684 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24703680 1.00 CNR2 (0.57) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL23052897 1.00 CNR2 (0.57) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL22957097 1.00 CNR2 (0.57) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL24703849 0.97 CNR2 (0.57) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL24703848 0.97 CNR2 (0.57) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL24703758 0.92 CNR2 (0.55) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL24703760 0.92 CNR2 (0.55) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL24703840 0.91 OPRM1 (0.56) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL22847424 0.85 CNR2 (0.56) CNR2CNR1OPRM1TRPV1TRPM8
SCHEMBL19941221 0.85 CNR2 (0.43) CNR2CNR1OPRM1TRPV1TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230284578-A1 EXTRACTS OF CBD AND THC NEXUS AGRISCIENCE, INC. 2023-09-14 US disclosed
US-11168047-B2 Cocrystal of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-l,3-diol ENANTIA, S.L. (ES) 2021-11-09 US disclosed
US-20200369586-A1 A COCRYSTAL OF 2-[(1R,6R)-6-ISOPROPENYL-3-METHYLCYCLOHEX-2-EN-1-YL]-5-PENTYLBENZENE-1,3-DIOL OSCITY, LLC 2020-11-26 US disclosed
US-20090275649-A1 Compositions And Methods For Identifying Modulars Of TRPV2 QIN NING 2009-11-05 US disclosed
US-7575882-B2 Compositions and methods for identifying modulators of TRPV2 JANSSEN PHARMACEUTICA N. V. (BE) 2009-08-18 US disclosed
US-7575882-B2 Compositions and methods for identifying modulators of TRPV2 JANSSEN PHARMACEUTICA N. V. (BE) 2009-08-18 US disclosed
US-20070105086-A1 Compositions and methods for identifying modulators of TRPV2 JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 US disclosed
US-20070105086-A1 Compositions and methods for identifying modulators of TRPV2 JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168047-B2 Cocrystal of 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-l,3-diol CBR1, CBR3, CYP2B6 CNR2 52/4885CNR1 13/4885OPRM1 57/4885
US-20200369586-A1 A COCRYSTAL OF 2-[(1R,6R)-6-ISOPROPENYL-3-METHYLCYCLOHEX-2-EN-1-YL]-5-PENTYLBENZENE-1,3-DIOL CYP2B6, CBR1, CYP2D6 CNR2 51/4885CNR1 14/4885OPRM1 44/4885
US-20090275649-A1 Compositions And Methods For Identifying Modulars Of TRPV2 TRPV2, TRPV1, TRPV3 CNR2 8/4885CNR1 21/4885OPRM1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.